hepatocellular carcinoma Gene Set

Dataset GWASdb SNP-Disease Associations
Category disease or phenotype associations
Type disease
Description A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.|Tumors or cancer of the LIVER.|A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation. --2002|A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation. (Experimental Factor Ontology, EFO_0000182)
External Link http://jjwanglab.org/gwasdb/gwasdb2/gwasdb2/go_trait/DOID:684
Similar Terms
Downloads & Tools

Genes

46 genes associated with the disease hepatocellular carcinoma in GWAS and other genetic association datasets from the GWASdb SNP-Disease Associations dataset.

Symbol Name Standardized Value
FUT6 fucosyltransferase 6 (alpha (1,3) fucosyltransferase) 3.99483
FUT2 fucosyltransferase 2 (secretor status included) 3.51446
ABO ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) 3.08092
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 2.6882
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 2.60668
FUT3 fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group) 2.40544
HLA-DQB2 major histocompatibility complex, class II, DQ beta 2 2.2205
FAM3B family with sequence similarity 3, member B 2.07237
RASIP1 Ras interacting protein 1 1.99432
KIF1B kinesin family member 1B 1.95032
AFP alpha-fetoprotein 1.93944
C2 complement component 2 1.91536
PPIP5K1 diphosphoinositol pentakisphosphate kinase 1 1.78856
DBP D site of albumin promoter (albumin D-box) binding protein 1.76717
SEC1P secretory blood group 1, pseudogene 1.76045
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 1.75616
DEPDC5 DEP domain containing 5 1.73479
MICA MHC class I polypeptide-related sequence A 1.71314
FUT1 fucosyltransferase 1 (galactoside 2-alpha-L-fucosyltransferase, H blood group) 1.69848
RPL18 ribosomal protein L18 1.65109
SULT2B1 sulfotransferase family, cytosolic, 2B, member 1 1.64472
B3GNT3 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 1.58623
STAT4 signal transducer and activator of transcription 4 1.5805
GRIK1 glutamate receptor, ionotropic, kainate 1 1.53058
GRIN2A glutamate receptor, ionotropic, N-methyl D-aspartate 2A 1.40417
MAP1A microtubule-associated protein 1A 1.35898
CA11 carbonic anhydrase XI 1.35121
CHST11 carbohydrate (chondroitin 4) sulfotransferase 11 1.34633
TP53BP1 tumor protein p53 binding protein 1 1.33817
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 1.31941
MTMR6 myotubularin related protein 6 1.28906
LRP1B low density lipoprotein receptor-related protein 1B 1.18963
EFCAB11 EF-hand calcium binding domain 11 1.07599
CHD6 chromodomain helicase DNA binding protein 6 1.06457
BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 0.958374
CD163L1 CD163 molecule-like 1 0.933664
SYNJ2BP synaptojanin 2 binding protein 0.846107
PC pyruvate carboxylase 0.822728
THSD7A thrombospondin, type I, domain containing 7A 0.783797
PODXL podocalyxin-like 0.743993
ADCY10 adenylate cyclase 10 (soluble) 0.733819
CASC15 cancer susceptibility candidate 15 (non-protein coding) 0.731217
C6ORF7 chromosome 6 open reading frame 7 0.712762
AJAP1 adherens junctions associated protein 1 0.711001
ZHX2 zinc fingers and homeoboxes 2 0.671205
TMTC1 transmembrane and tetratricopeptide repeat containing 1 0.609075